Cronos Group (CRON) – Investment Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Cronos Group (NASDAQ: CRON):

• 3/2/2026 – Cronos Group was downgraded by Weiss Ratings from “hold (c)” to “sell (d+)”.
• 2/28/2026 – Cronos Group was downgraded by Wall Street Zen from “hold” to “sell”.
• 2/24/2026 – Cronos Group is now covered by TD Securities. They set a “buy” rating on the stock.
• 2/14/2026 – Cronos Group was upgraded by Wall Street Zen from “sell” to “hold”.
• 1/31/2026 – Cronos Group was downgraded by Wall Street Zen from “hold” to “sell”.
• 1/27/2026 – Cronos Group is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating on the stock.
• 1/14/2026 – Cronos Group had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $2.30 price target on the stock.
• 1/6/2026 – Cronos Group was downgraded by Zacks Research from “strong-buy” to “hold”.

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.